Overview
STEP-1 through STEP-4 trials established semaglutide's weight-management efficacy. Pivotal STEP-1 (NEJM 2021, PMID 33567185): 14.9% mean weight loss at 2.4 mg / 68 weeks.
PubMed citations
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
In STEP 1 (NEJM 2021), adults with obesity or overweight and no diabetes lost an average of 14.9% of body weight at 68 weeks on semaglutide 2.4 mg, against 2.4% on placebo. At least 5% weight loss was reached by 86.4% versus 31.5%, at least 10% by 69.1% versus 12.0%, and at least 15% by 50.5% versus 4.9%. Average weight change was −15.3 kg versus −2.6 kg. Later STEP trials tested continued treatment and two-year use. These results come from FDA-approved Wegovy, not compounded semaglutide.